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ABSTRACT OF THESIS

BONE ENGINEERING OF THE ULNA OF RABBIT

Repair of bone defects is a major challenge in orthopaedic surgery. Current bone graft
treatments, including autografts, allografts and xenografts, have many limitations making
it necessary to develop a biomaterial to be a bone graft substitute. One such biomaterial is
bioactive resorbable silica-calcium phosphate nanocomposite (SCPC). SCPC was
processed using a 3D rapid prototyping technique and sintered at different temperatures
to create porous scaffolds. SEM analyses and mercury intrusion porosimetry showed
SCPC to be highly porous with micro- and nanopores. BET analysis indicated that SCPC
had high surface area. Mechanical testing demonstrated that SCPC had a compressive
strength similar to trabecular bone. Analysis of different thermal treatment temperatures
indicated as the temperature was increased, the porosity decreased and the mechanical
strength increased. When loaded with rhBMP-2 (SCPC-rhBMP-2), SCPC provided a
sustained release profile of rhBMP-2 for 14 days. This was shown to be a greater release
than hydroxyapatite (HA)-rhBMP-2. After immersion in SBF, ICP analyses showed the
calcium concentration of SBF dropped drastically after one day of immersion. In
conjunction, FTIR showed the formation of a hydroxyapatite layer on the SCPC surface
and was confirmed by SEM. SCPC thermally treated at 850 ºC demonstrated the greatest
dissolution/precipitation reactions when immersed in SBF. Processing the SCPCrhBMP-2 hybrid using a rapid prototyping technique allowed for an exact replica of the
rabbit ulna to be fabricated. This was implanted into a 10 mm segmental defect in the
rabbit ulna. CT scans during the healing of the defect showed intimate union between
SCPC-rhBMP-2 and the bone and about 65% healing of the defect after 4 weeks. Rabbits
were euthanized after 12 and 16 weeks. Digital images show almost complete healing of
the defect after 16 weeks. Torsional testing of the ulna after 12 weeks demonstrated
restoration of maximum torque and angle at failure. Histological evaluation after 12
weeks showed the regenerated bone has all the morphological characteristics of mature
bone. Through in-vitro and in-vivo testing, it can be recommended that the porous
bioactive SCPC can serve as a successful delivery system for biological growth factors
and serve as an alternative to autologous bone grafting.
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Chapter 1
Introduction

1.1 Bone Grafts

Skeletal deficiencies that result from trauma, tumors or abnormal development frequently
require surgical intervention in order to restore normal tissue function [1]. In the US
alone there are over 2.2 million orthopaedic procedures performed each year, 450,000 of
those being bone graft procedures. This makes bone the most common tissue for
transplant procedures, second only to blood [2].

Although current surgical treatments

are often successful in repairing bone defects, they all have problems and limitations.
Bone grafts are needed when part of your body is missing bone. This missing portion of
bone is frequently called a bone defect. A bone graft is a surgical procedure that replaces
the bone defect with material from the patient's own body or an artificial, synthetic, or
natural substitute. The purpose of the graft is not only to replace the missing bone, but
also to stimulate new bone formation in the bone defect area [3]. The graft forms a bridge
and acts a scaffold in the defect area until new bone can grow in its place. Eventually the
newly formed bone should completely replace the bone graft material.

1.1.1 Autografts

Currently there are three main types of biological bone graft procedures. The first is the
autograft, the “gold standard” method for repairing bone [3]. This is where bone is
harvested from a patient’s own body, typically from the pelvis or iliac crest. Autogenous
bone grafts provide both osteoinductive and osteoconductive stimuli for bone growth.
They can be used to not only provide mechanical support but also to stimulate new bone
formation. Autogenous bone grafting has excellent fusion rates and has become the
1

standard by which all other bone grafts are measured. Many surgeons prefer autogenous
bone grafts because there is no risk of the body rejecting the graft since it came from the
patient's own body. However, the success of the autograft is often compromised due to
its many limitations. These include the fact that removing bone from one part of the
body creates the same deficit there as in the area being repaired, possible donor site
morbidity, limited donor bone supply, anatomical and structural problems, high costs,
and the need for multiple surgeries [3].

1.1.2 Allografts and Xenografts

In an effort to minimize the problems associated with taking the patient's own bone, a
common alternative to the autograft is the use of allograft or xenograft bone. An allograft
bone graft is bone harvested from deceased individuals who have donated their bone for
use in the treatment of living patients. The advantage of the allograft is that multiple
surgeries within the same patient are not required. However, the shortcomings greatly
outweigh the benefits [2]. The downfalls to the use of allografts are the necessity of
having compatibility between donor and recipient, it does not promote bone growth very
well, there is limited donor supply, and diseases may be transmitted together with the
implant [4].
The third type of biological bone graft is the xenograft. A xenograft is a graft in which
bone tissue is taken from another species. Xenografts are biocompatible and are also
osteoinductive in nature. Contrary to the auto- and allograft, xenografts are available in
almost endless supply.

However, like allografts, xenografts have problems with

compatibility between donor and recipient, and possible disease transmission.

2

1.1.3 Synthetic Grafts

In order to offer the advantages of the autograft, allograft, and xenogaft and eliminate the
limitations, it is necessary to develop a biomaterial to be used as a bone graft substitute.

1.1.3.1 Bioceramics
Bioceramics, such as hydroxyapatite (HA), tricalcium phosphate (TCP), and bioactive
glass (BG), are one type of biomaterial that is being used as synthetic bone grafts. These
synthetic materials have similar surface structure to that of natural bone, making them
osteoconductive. Most osteoconductive materials bond to bone and allow direct bone
deposition on their surface. Synthetic porous bioceramics are primary candidates as bone
substitutes due to not only their excellent osteoconductive properties, but they are
available in unlimited supply, and they can have custom-designed shape and size. They
are not associated with disease transmission, cause neither chronic inflammation nor
systemic toxicity, and there is no foreign body response nor any evidence of rejection [5].
They are available in many forms such as porous particles and pastes [6]. Although
ceramics may provide a scaffold for bone growth, they are not osteoinductive, meaning
they do not have the ability to enhance osteogenic differentiation of osteoblastic cells.
Also, the application of porous ceramics for load-bearing conditions is difficult due to
their adverse mechanical properties; they are brittle, have low impact resistance, and have
low tensile strength [5].

1.1.3.2 Polymers

Polymers such as poly(lactic) acid (PLA), poly(glycolic) acid (PGA), and their copolymers (PLGA), and are often used as bone graft substitutes. These materials have the
advantage of altering their chemical structure so that they can be integrated with growth
factors, drugs, and other compounds to create delivery systems. They are biocompatible,
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resorbable, can be processed into porous scaffolds that have mechanical properties
similar to that of bone. However, some polymers are not osteoconductive and it has been
found that as certain polymers degrade, they release acidic by-products which can inhibit
new bone formation and even cause bone resorption [7, 8].

1.1.3.3 Metals

Metals are another type of synthetic biomaterial that can be used as a biomaterial for
bone defects. Metals such as titanium and titanium alloys, stainless steel, and cobaltchromium have been widely used in the orthopaedic field and can be utilized in loadbearing conditions. This is due to their excellent mechanical characteristics in terms of
stiffness and elasticity and bone compatibility [9]. Conversely, most metals are not
osteoconductive, and none are osteoinductive, or resorbable.

1.1.3.4 Composites

Composite bone grafts are the combination of multiple biomaterials. These are used in
order to maximize the advantages and minimize the limitations of these synthetic graft
materials. Such combinations of these include ceramic-metal, ceramic-polymer, ceramicceramic. In combining a ceramic with a metal, the composite can have the mechanical
strength of a metal while taking on the osteoconductive property of a ceramic. By
combining a ceramic with a polymer, the structure of the biomaterial is less brittle than a
ceramic alone and the polymer can become osteoconductive. Combining different
biomaterials can create a composite that is porous, resorbable, biocompatible,
osteoconductive, and has good mechanical strength. Yet, in developing a biomaterial as a
bone graft substitute it is not only necessary to fill the bone defect with an
osteoconductive scaffold, but to seed that scaffold with osteoinductive growth factors that
will stimulate new bone tissue to grow in and around the porous scaffold.

4

1.2 Tissue Engineering

Tissue Engineering is a multidisciplinary field that combines the principles of biology
and engineering to develop tissue substitutes to restore, maintain, or improve the function
of diseased or damaged tissues, such as bone. Cytokine therapy is one area of bone tissue
engineering that involves seeding highly porous, biodegradable scaffolds with growth
factors, then implanting the scaffolds to induce and direct the growth of new, healthy
bone at a target site [10, 11]. For a scaffold to be used as a tissue engineering scaffold it
should fulfill three primary purposes [12]. First, it should geometrically replicate the size
and shape of the defect. Second, it should temporarily fulfill the physical function of the
bone tissue it is replacing.

Finally, the scaffold material composition and porous

microstructure should enhance tissue regeneration.

1.2.1 Growth Factors

Growth factors, such as bone morphogenetic proteins (BMPs) and transforming growth
factors (TGF-β), are osteoinductive agents that occur naturally in bone. Growth factors
are very powerful stimulants for bone formation and can be used alone or with a carrier
system as graft replacements. These biologically active proteins play a key role in the
body's own natural bone-forming process and are found naturally at sites of bone
fracture. These proteins can be produced, concentrated and placed in the body in areas
where bone formation is needed and are powerful enough to stimulate bone formation
without the need for taking the patient's own bone.
BMPs are a subgroup of factors in the TGF-β superfamily and consist of a family of at
least 15 structurally related osteoinductive growth factors.

They were originally

identified as protein regulators of cartilage and bone formation.

There are several

different BMPs naturally found in the body and many play a critical role in bone
formation. The most promising proteins are BMP-2 and BMP-7 [13]. These two proteins
have been extensively studied in animals and humans with very promising results [14].

5

Both proteins have shown to successfully stimulate new bone formation in defect sites
and with higher success rates when used alone as compared to using the patient's
autogenous bone graft. They accomplish this by inducing differentiation of stem cells
into osteogenic bone forming cells.
Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a substance that was
cloned by Wozney et al. [15]. rhBMP-2 stimulates the expression of differentiation
markers of osteoblasts in-vitro [16] and initiates a complex series of cellular events
culminating in bone formation [17]. Although BMP can induce bone formation at a
defect site alone, due to its short half-life, rapid diffusion and degradation [16] the dose
needed to induce this bone formation can be quite high. This dose can be greatly reduced
when BMP is combined with an appropriate biodegradable scaffold carrier that can
immobilize the protein while retaining its bioactivity [18]. In addition to reducing the
dose needed for bone induction, a carrier acts as a means of deployment for BMP. By
attaching BMP to a delivery system, the bioactivity of the protein can be maintained for a
longer period of time and the protein can be held in place at the target site [11]. A carrier
must not inhibit the bone formation and bone repair capability of the BMP [11]. When
used with a biomaterial carrier system, BMP has been shown to stimulate bone
formation, alkaline phosphatase activity, collagen synthesis, and osteoblast differentiation
[19].

1.2.2 Ideal Characteristics of BMP Carrier

One of the major functions of a delivery system for BMPs is to retain BMP at the grafted
site for a period of time sufficient to induce bone [20] so that the molecules can exert
their biological action. Therefore, a carrier should have controlled release kinetics of
BMP, meaning it has the ability to deliver the growth factor at the appropriate time and in
the proper dose [14].

6

Another major function is to provide an initial substratum for the growth and
differentiation of bone-forming cells. In order to be this initial substratum, a bone tissue
engineering scaffold must possess certain characteristics.

First of all, the tissue

engineered scaffold should be biocompatible and not elicit an inflammatory or
immunogenic response in the body [20].
An ideal biomaterial carrier should also be highly porous providing a pathway of
interconnections through which new cells can migrate and new blood vessels can form. If
the pore size of the biomaterial exceeds 100 µm, bone will grow within the
interconnecting pore channels near the surface and maintain its vascularity and long-term
viability [21]. Although, for a resorbable material, the immediate resorption that takes
place when it is immersed in a physiological solution will increase its pore sizes,
eliminating the need for the initial porosity of the biomaterial to be specifically defined.
Nevertheless, the implant should serve as a scaffold for bone formation, maintaining
surface area and volume to facilitate directional bone formation [22]. A porous scaffold
also provides an appropriate surface environment in which cells can adhere and
proliferate.
A biomaterial also needs to be osteoconductive and have the ability to promote bone
growth by allowing bone formation on its surface.

Biomaterials with good

osteoconductive properties can form a tight bond with the host bone tissue, a
characteristic which is desirable for the restoration of bone function at a defect site [20].
The biomaterial also should be osteoinductive, stimulating new bone formation. And
osteoinductive means that the material will enhance osteogenic differentiation of
osteoblatic cells, the cells that will build new bone.
The biomaterial should also ideally be resorbable, so that as new bone grows, the scaffold
can slowly degrade away and eventually be completely replaced by newly regenerated
bone [20]. The degradation rate of the biomaterial needs to be controlled so that it does
not degrade away too quickly before new bone can grow in its place, or too slowly
inhibiting new bone formation.

In addition, when used as a carrier for BMP, if a

7

biomaterial degrades too fast the BMP may be released too rapidly and the risk of fibrous
ingrowth, and failure of bone healing, is increased.
In order for the biomaterial to initially replace bone, it needs to exhibit similar
mechanical properties of bone [21]. If used in a load bearing situation, the scaffold needs
to possess enough rigidity to be able to withstand the forces that are going to be applied
to it. But there is a trade off between porosity, which is important, and mechanical
strength [5]. As the porosity increases, the mechanical strength is going to decrease.
There needs to be a balance between the two so that the stimulation of new bone
formation can be greatest.
Because no bone in the body is a perfect cylinder of rectangle, the geometry of the
scaffold must also be appropriate for the implantation site, as it will define the area in
which the bone is formed [11]. A precise geometry is not only important in order to
achieve maximum restoration of function, but also for cosmetic reasons as well. This is
especially true for maxillofacial bone graft procedures. In addition, since the size and
shape of an implant can influence the degradation rate of the carrier, the rate of release of
BMP, and the bonding of bone to the implant, it is essential to have a scaffold that is the
exact shape of the specific bone defect that it is temporarily replacing.

1.2.3 Current BMP Carriers

1.2.3.1 Collagen

The most common scaffold materials used as BMP carriers include collagen and
biodegradable polymers [9, 23].
Collagen is a fibrous protein that is abundantly found in the extracellular bone matrix.
The porous structure of collagen makes it conducive to mineral deposition, vascular
ingrowth, and growth-factor binding. This structure provides both a physical and
8

chemical environment that is favorable to new bone regeneration. Absorbable collagen
sponges have served as carriers for growth factors, limiting the diffusion of rhBMP-2
through collagen-rhBMP-2 interactions and physical trapping [24]. These interactions
have assisted in establishing a prolonged release of BMP at the target site. However,
collagen provides little or no initial structural support and has potential immunogenicity
[2].

1.2.3.2 Polymers

Polymers are biomaterials that have been applied in clinical practice in fracture fixation
for over 20 years. The most popular of the polymers used are PLA, PGA, and PLGA.
Because of their biocompatibility and their ability to bind proteins, polymers have been
widely used as scaffolds to deliver BMP. Polymers are a promising material for BMP
delivery since their chemical structure, and thus its release kinetics of BMP, can be easily
altered. Polymers can be made into porous, resorbable scaffolds that have the proper
mechanical strength in order to replace bone. One study reported that encapsulation of
BMP with a biodegradable PLGA is an effective polymeric vehicle for the controlled
release of BMP [1]. However studies have shown that as some polymers degrade,
isolated areas of fragmentation and degradation of the polymer scaffold had elevated
areas of inflammatory response cells [7, 8]. As polymers degrade they can release acidic
by-products that have adverse foreign body reactions.

1.2.3.3 Calcium Phosphates

Another major group of biomaterials that are used as carriers for BMP delivery are
calcium phosphate-based bioceramics. Calcium phosphates have been used in medicine
and dentistry for nearly 30 years [22]. They are widely used as bone substitutes due their
high bioactivity. They have been known to easily bond to bone and enhance bone tissue
formation. Calcium phosphates can be classified as non-resorbable or resorbable. Two
of the forms of calcium phosphate ceramics that are most widely used are TCP and HA.
9

Both have similar structures to that of bone and have been shown to be osteoconductive
[25]. Calcium phosphate ceramics can be processed to be porous scaffolds and because of
this have been widely used as tissue engineering scaffolds for the delivery of growth
factors [21, 26-29]. One study investigated a porous calcium phosphate ceramic with
micro-porous structures, which consisted of HA and a trace of α-TCP, as a BMP carrier
[29]. Mature lamellar bone was found in the implants after 35 days, indicating the
calcium phosphate ceramic was an effective carrier of BMP.
Unfortunately, calcium phosphate ceramics also exhibit many limitations. When calcium
phosphate ceramics have been used as carriers for BMP delivery they have often elicited
inflammatory and immunologic reactions [30]. It has been found that porous TCP
ceramics are dissolved and resorbed relatively quickly and do not have good mechanical
stability [5]. Moreover, this adversely high-dissolution rate has been associated with an
elicited immunologic response [31]. As for HA, although it has been shown that bone
does grow in porous and dense HA particulates, the bone conductivity is limited [25].
The major limitation in using calcium phosphate ceramics is their poor mechanical
properties. They have been shown to be brittle, so when implanted in place of bone there
is minimal immediate structural support.

1.2.3.4 Bioactive Glasses

Bioactive glass is another calcium-phosphate based bioceramic used to replace bone that
can be considered as a BMP carrier.

Besides being composed of calcium and

phosphorus, another major component is silica. Due to its amphorous structure, it is
known to have a stimulatory effect on bone cell function, making it a favorable bioactive
biomaterial. As compared to HA, BG accelerated bone growth 3 times more when
implanted in bone [32]. Bioactive glasses form a tight bond with surrounding tissues by
the in-vivo formation of a biologically active carbonate-containing hydroxyapatite layer
(HCA) on the glass surface. However, BG is a solid non-resorbable material [33].
Therefore, when synthesized as a nonporous carrier for the delivery of BMP, the growth
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factors can only be seeded onto the outside of the BG scaffold. Upon implantation this
would cause an immediate release of all the protein. As discussed before an appropriate
carrier would retain the BMP at the grafted site for a period of time sufficient to induce
bone.

1.2.3.5 Composites

Now the previously mentioned carriers all had different characteristics that set them apart
as possible delivery systems for BMP. But none of them seemed to have all of the
qualities necessary to make them that perfect tissue engineering scaffold for BMP
delivery. A composite graft can combine different carriers so that the weaknesses of one
are overridden by the strengths of another. One example of a composite graft could
combine an osteoconductive biomaterial with a biomaterial that provides good
mechanical properties, potentially replicating bone functionality. One study combined a
titanium mesh and calcium phosphate ceramic [27]. The titanium mesh provided the
composite with excellent mechanical properties and biocompatibility.

The calcium

phosphate coated the titanium mesh and provided the osteoconductivity to the composite.
Another example of a composite could be a polymer-ceramic composite.

A study

combined the synthetic biodegradable polymer PLA with interconnected-porous calcium
HA [10]. This composite combined the strength of the polymer with the
osteoconductivity of the ceramic.

When implanted in a critical sized defect, the

composite graft induced new bone formation in the pores and around the implant with
sufficient strength and anatomical structure.

1.2.3.5.1 Silica-Calcium Phosphate Composite

Another composite biomaterial is the one being used in this study. This composite
biomaterial has been developed to possess all of the characteristics needed in order to be
a tissue engineering scaffold for BMP delivery and bone regeneration. This material is
SCPC or silica-calcium phosphate composite. This biomaterial is resorbable, porous, and
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bioactive. Previous studies in our lab have shown that SCPC has superior stimulatory
affects on bone tissue regeneration when compared to BG or HA ceramic. Moreover,
when the material was used as a carrier for BMP, the SCPC-rhBMP-2 hybrid provided a
sustained release profile of biologically active rhBMP-2 and enhanced mesenchymal
stem cell differentiation and bone tissue formation in-vitro.

1.3 Processing and Fabrication of Tissue Engineering Scaffolds

Once a biomaterial is found that meets all of the qualifications of a tissue engineering
scaffold for BMP delivery and bone regeneration, it must be processed into a scaffold.
For bone tissue engineering, the bone graft substitute needs to have adequate porosity for
bone repair so as to accelerate bone regeneration. The scaffold must also replicate the
size and shape of the defect it is going to fill. Both of these characteristics synergistically
play an integral role in the success of the bone substitute. And accurate repair of bone
defects is not only important in obtaining restoration of bone function but is also
important for cosmetic reasons as well. This is especially true for maxillofacial bone
reconstructions. Yet many studies that have engineered biomaterials to fill irregular bone
defects use cylinders or blocks [10, 23, 26, 31, 34].
Traditional processing of biomaterials has demonstrated scaffolds with limited control
over geometry and porosity. These include polymer foaming technique, particulateleaching, solid–liquid phase separation, textile technique, and extrusion process [35].
These primitive methods create scaffolds which are cylinders, blocks, particles or pastes.
The structure of these types of scaffolds does not mimic that of bone, which is essential
to vascularization and tissue regeneration.

1.3.1 Rapid Prototyping Technologies

The novel technologies of solid freeform (SFF) or rapid prototyping (RP) are becoming
the choice for scaffold processing, due to the ability to engineer scaffolds with predefined
12

and reproducible internal morphology that replicates that of natural bone. SFF
technologies involve designing a scaffold model with 3D computer aided design (CAD)
or obtaining data originating from computed tomography (CT) or magnetic resonance
imaging (MRI). This digital information can then be converted to a machine specific
cross-sectional format, expressing the model as a series of layers. This data is then used
by the SFF machine which produces a physical model in a layer-by-layer method.
Through this type of processing technology, it is possible to control scaffold architecture,
material composition, and porosity which are all critical factors in the development and
future success of tissue engineering.

1.3.1.1 Fused Deposition Modeling

Currently, there are only a few SFF techniques that are being used for scaffold
processing.

One such RP technique that has been extensively researched is fused

deposition modeling (FDM) [35-38]. FDM uses the concept of melt extrusion in order to
deposit a parallel series of material roads that forms a material layer. For this type of
scaffold fabrication, a filament material stock is fed and melted inside a heated liquefier
head and then is extruded through a nozzle with a small orifice. For each deposited
material layer, the direction of material deposition can be changed. By changing the
direction of material deposition for consecutively deposited layers and the spacing
between the material roads, scaffolds with highly uniform internal honeycomb-like
structures, controllable pore morphology and complete pore interconnectivity are
obtained, simulating the internal structure of bone.

1.3.1.2 Selective Laser Sintering

Another SFF technology that has been adapted for fabricating tissue engineering
scaffolds is selective laser sintering (SLS) [38]. This technology utilizes a CO2 laser
beam to selectively sinter polymer or composite powders to form material layers. The
laser beam is directed onto a powder bed by a high precision laser scanning system.
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Subsequent stacking and fusion of the sintered material layers creates a scaffold that
replicates the object’s height. Due to the powders being subjected to low compaction
forces during their deposition to form new layers, this technology creates objects which
are porous.
1.3.1.3 Three-Dimensional Printing

The most commonly used SFF technology is three-dimensional printing (3D-P) [38].
This technique employs the technology of ink jet printing for the processing of materials
in powder form. Because of the versatility and simplicity of 3D-P, it allows for the
processing of a wide variety of biomaterials that include polymers, metals and ceramics.
During fabrication of a scaffold, a printer head is used to print a liquid binder onto thin
layers of selected powder. The binder sprays an area that is the same as the scaffold’s
cross-sectional area as generated by a system computer. The successive stacking and
printing of material layers onto the top of previously printed layer recreates an exact
replica of the desired object. After sintering this fabricated material, the binder is burned
away leaving a highly porous scaffold.

1.3.1.3.1 Z-Corp Processing

One specific example of 3D-P called Z-Corp processing was used in this study. A ZCorp 3D printer was used in order to fabricate porous disk scaffolds for in-vitro testing,
and exact replicas of rabbit ulna segmental bone defects for in-vivo testing.

By

combining Z-Corp processing with SCPC powder, highly porous, bioactive, resorbable
tissue engineering scaffolds were fabricated in only minutes.

These scaffolds were

processed with an adequate porosity for bone repair, and a specific geometry, replicating
the size and shape of the defect it was going to fill.
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1.4 Objectives

The main goal of this study was to employ a 3D processing technique with the SCPC
powder to develop a tissue engineering scaffold for BMP delivery and bone regeneration
in a load bearing segmental bone defect. The specific objectives were:
1

Evaluate the effect of different thermal treatment temperatures on the mechanical
strength, porosity and surface area of SCPC.

2

Evaluate the effect of thermal treatment on the dissolution kinetics of the material
in physiological solution.

3

Correlate the physicochemical properties of the material to the development of
bioactive surface layer on the SCPC in physiological solution.

4

Study the release kinetics of rh-BMP-2 from SCPC-rh-BMP-2 hybrid in
physiological solution.

5

Test the ability of the SCPC-rhBMP-2 hybrid to enhance bone regeneration in a
load bearing large bone defect in the ulna of rabbit.

Copyright © Amanda Peter Hart 2005
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Chapter 2
Materials and Methods

2.1 In-Vitro Study

2.1.1 Sample Preparation

Table 2.1.1 shows the chemical compositions of the silica-calcium phosphate composite
and hydroxyapatite (ProOsteon® 200HA) that were used in this study. Previous studies
in the lab have shown that the composition of ratio 75:25 Sodium Silicate to Calcium
Phosphate has high bioactivity [33]. Batches of 100 g of the composition were placed in
polyethylene bottles and placed on a roller mixer and allowed to mix for 24 hours to
ensure even distribution of the powders. Each batch was moistened with 0.1% NaOH
until a paste was formed and spread into a prefabricated teflon mold with 10 mm
diameter × 10 mm height cylindrical cutouts. The SCPC samples were left to dry at room
temperature and then thermally treated (Thermolyne 30400 Furnace, Sybron/Thermolyne
Corporation, IW, USA) at 100 ˚C for 1 hour and then 800 ˚C for 1 hour.

2.1.2 Z-Corp Processing

Particles in the size range 45-90 µm were prepared by grinding the SCPC using a mortle
and pestle then sieving to achieve the desired particle size range. These particles were
then processed using a Z-Corp 3D Printer (Z402 System, Z Corporation, Burlington, MA,
USA). Z-Corp printers use a powder-binder technology to create parts directly from
digital data. In order to get the desired shape to be modeled by the Z-Corp, the first step
is to obtain high resolution MRI or CT data of the area of interest. This data is then
converted into a stereolithography (STL) data format, which remaps the surface data to a
series of triangles that when assembled reconstruct the original geometry. This
16

Table 2.1.1: Chemical Composition of SCPC and HA in mol %
Composite code

Na2O

SiO2

CaO

P2O5

SCPC

32.9%

32.9%

22.8%

11.4%

HA

0

0

76.9%

23.1%
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file is then imported into a computer aided design (CAD) software package (Amira,
Amira 3D Professional Visualization, Berlin, Germany). This step allows adjustments to
the image to be made. The final CAD image is then converted back into a STL format,
and then into a slice file that the Z-Corp machine will use in order to replicate the model
layer by layer. The thickness of each of these layers can be 0.076 - 0.254 mm. To
process the desired prototype, first the Z-Corp spreads out a thin layer of the SCPC
powder (Figure 2.1.2). Then, an ink-jet print head prints a water-based binder, made of
water and agar, in the cross-section of the part being created. Next, the build piston drops
down, making room for the next layer, and the process is repeated. Once the part is
finished, it is surrounded and supported by loose powder, which is then shaken loose
from the finished part. After building the prototype, any unused powder is collected and
can be reused.
In order to make SCPC disks using the Z-Corp machine for in-vitro testing, the disks
were first constructed in CAD software, converted to STL format and then a slice file
which was used to process the SCPC disks using the Z-Corp machine. Disks of size 10
mm diameter x 10 mm height were constructed for material characterization and disks of
size 10 mm diameter x 2 mm height were processed to study the interaction of the SCPC
with simulated body fluid (SBF). These disks were all processed using the Z-Corp
machine in only minutes.

2.1.3 Effect of Thermal Treatment

SCPC disks were first thermally treated at a lower temperature to burn off the binder, and
then sintered at a higher temperature to fuse the SCPC particles. In order to determine
the thermal treatment required to burn off the hydrocarbons from the SCPC disks, several
different temperatures were evaluated. SCPC disks (n=3) were treated at 300, 350, 400,
or 450 ºC for 24 hours. If the hydrocarbons were not completely burned away the
samples were left with a grayish color. The SCPC disks treated at 450 ºC were white
after 24 hours of thermal treatment. Next, different thermal treatment durations were
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Figure 2.1.2: Video of Z-Corp Processing
To begin building an implant the printer head sweeps across the feed and build boxes.
The feed box rises supplying a thin layer of SCPC powder and the printer head pushes
that across to the build box. Then the printer head sweeps across the build box, spraying
a layer of the binder that is the same as the first cross-section of the part. The feed box
will rise by one layer height and the build box will lower by one layer. The printer head
will then push the next layer over to the build area creating the next layer. This process is
then repeated over and over until the implant is created. The printer head will spray the
binder, the feed box will raise, the build box will lower and the printer head will push the
powder over creating the next layer. Excess powder is removed and the finished implant
is removed from the Z-Corp. Any unused SCPC powder can then be recycled and used
again.
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evaluated in the same way. SCPC disks (n=3) were thermally treated at 450 ºC for 16,
18, 20 or 24 hours. It was found that treating the disks at 450 ºC for 18 hours sufficiently
burned away all the hydrocarbons from the SCPC disks.
The effect of thermal treatment on the physicochemical properties of the SCPC material
was then investigated for the sintering temperatures 800, 850, and 900 ºC.

These

treatment temperatures allowed for the formation of interconnectivity between the pores
of the SCPC disks.

2.1.4 Material Characterization

2.1.4.1 Surface Characterization

To analyze the morphology of the SCPC disks, high resolution images were obtained by
scanning electron microscope (SEM) operated at 20 kV acceleration voltage. First the
disks were mounted on SEM stubs using colloidal graphite. The colloidal graphite was
painted around the edges of the disks to facilitate electron conduction. The disks were
then gold coated under an argon atmosphere using an Emscope SC400 sputter coater.
This was done in order to facilitate electron conduction and assist the flow of electrons on
the surface of the SCPC disks. The samples were then loaded into the microscope
(Hitachi S-3200, Tokyo, Japan) and analyzed in the secondary image mode (SI).

2.1.4.2 Porosity Measurements

The porosity percent and specific surface area of SCPC disks processed using the Z-Corp
machine and thermally treated at 800, 850, and 900 ºC were determined with the use of
mercury intrusion and gas adsorption techniques (Micromeretics Co., Norcros, GA). The
surface area of the samples was determined using the BET (Brunauer, Emmet, and
Teller) theory. The thermally treated samples were cooled with liquid nitrogen and
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analyzed by measuring the volume of gas (N2) adsorbed at specific pressures.

To

measure the porosity percent and pore size distribution, mercury intrusion porosimetry
was used. This technique involved placing the SCPC disks in a penetrometer, then
surrounding the sample with mercury. Mercury was used because it is a non-wetting
liquid to most materials and it resists entering voids or pores, doing so only when
pressure is applied. The pressure applied to the mercury was increased from 0 psia to
60,000 psia.

The pressure at which the mercury entered the pore was inversely

proportional to the size of the pore.

2.1.4.3 Mechanical Properties

The compressive strength of the porous SCPC disks (10 mm diameter x 10 mm height)
(n=5) which were subjected to various thermal treatments were evaluated using an
Instron Machine Model 5582. The SCPC disks were loaded uniaxially at a rate of 0.005
in/sec until failure at room temperature.

Load and displacement were measured

continuously by the Instron testing machine and recorded. From this measured data, a
stress-strain curve was derived and used to calculate ultimate compressive strength and
failure strain of the SCPC disks. In addition, the values for the compressive modulus
were derived from the stress-strain curves.

2.1.4.4 Evaluation of Release Kinetics of rhBMP-2

2.1.4.4.1 Recombinant Human BMP-2 Preparation

The recombinant human BMP-2 (rhBMP-2) used in this study was supplied by R&D
Systems, Inc. (Minneapolis, MN). In order to reconstitute the 10 µg rhBMP-2 protein,
300 µL of 4 mM HCl containing 0.1% BSA (albumin bovine serum) was added to the
protein, preparing a stock solution of 1 µg per 30 µL.
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2.1.4.4.2 Release Kinetics of rhBMP-2

The SCPC implants (10 mm height x 5 mm width) (n=5) processed using the Z-Corp 3-D
printer then thermally treated at 800, 850 or 900 ºC, and HA disks (10 mm diameter x 4
mm height) (n=5) were placed separately in a 24-well plate and sterilized by 100%
ethanol for 30 min and then allowed to dry. Then the SCPC implants and HA disks were
individually loaded with 30 µL of the reconstituted rhBMP-2. After the rhBMP-2 was
evenly distributed on the ceramics, they were allowed to dry for 1 h. Next, each sample
was individually placed in a snap cap vial and immersed in 10 mL of phosphate-buffered
saline (PBS; pH 7.4) containing 1% BSA. All of the samples were placed in an incubator
at 37 ºC for a period of 14 days. After various time periods, 1, 2, 4, and 12 hours, and 1,
2, 4, 6, 8, 10, 12 and 14 days, 2 mL of the existing immersion PBS solution were
exchanged with 2 mL of fresh PBS solution. The concentration of BMP-2 released from
the SCPC implants and the HA disks into the immersing solution was quantified with a
Quantikine BMP-2 ELISA kit from R&D Systems, Inc. (Minneapolis, MN). The optical
density of each well was determined using a microplate reader set to 450 nm. In order to
account for wavelength correction, the optical density was also measured at 570 nm and
subtracted from those readings done at 450 nm.

From the rhBMP-2 standard dilutions

supplied in the ELISA kit, the optical density versus the known concentration of the
standards was plotted and a best-fit curve was drawn. The rhBMP-2 concentration of
each sample could be determined by finding the absorbance value on the y-axis and using
the best-fit curve, and then finding the corresponding rhBMP-2 concentration from the xaxis. Since after each time point the samples were diluted, the concentrations were
multiplied by a dilution factor of 1.25 for each time point.
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2.1.5 Study of the Interaction of SCPC with Simulated Body Fluid

2.1.5.1 Preparation of Simulated Body Fluid

In order to replicate that results that would occur in-vivo, the SCPC disks were immersed
in simulated body fluid (SBF) (Table 2.1.5.1). According to Kokubo [39], this solution
can precisely reproduce in-vivo surface structure changes, due to its similar ion
concentration to human blood plasma.

2.1.5.2 Immersion Study

SCPC disks (10 mm diameter x 2 mm height), pre-treated at different temperatures, were
placed in 6-well plates and immersed in 6 ml SBF for 12 hours, 1, 3, or 5 days. The
plates were incubated at 37 ºC for the duration of the immersion time. At the end of each
time period, the disks were removed from the SBF, rinsed with deionized water, dried at
room temperature and used for surface analyses. The immersion SBF solution was
dispensed into 15 ml centrifuge tubes and stored in a freezer for the analysis of SCPC
dissolution kinetics.

2.1.5.3 SCPC Dissolution Kinetics

After immersion of the SCPC disks, the SBF ionic concentrations were analyzed by
inductively coupled plasma-optical emission spectrometry (ICP-OES) (Perkin Elmer
Optima 2000 DV, Wellesley, MA, USA). To analyze the concentrations of Ca, P, and Si,
the collected SBF was diluted 3 times. To analyze the Na concentration, the SBF was
diluted 36 times. These dilutions were necessary due to the ionic concentrations of the
SBF being too high to be quantified by the machine. As a washing solution, 0.01% Triton
X was prepared. Diluted SBF samples were placed in the autosampler tray along with the
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Table 2.1.5.1: Simulated Body Fluid Concentrations
Concentrations (mM)
Na+

142.0

K+

5.0

Mg2+

1.5

Ca2+

2.5

Cl-

148.8

HCO3-

4.2

HPO42-

1.0
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standards of Ca, P, Si, and Na. The samples were then fed into the plasma. Atoms in the
plasma emit photons with characteristic wavelengths for each element being analyzed.
This photon emission is recorded by an optical spectrometer and when calibrated against
the standards, this technique provided a quantitative analysis of the ionic concentrations
of the SBF samples.

2.1.5.4 Surface Chemistry Analysis

To analyze modifications in the surface chemistry during immersion in SBF, the
functional groups on the surface of the SCPC disks, before and after immersion in SBF,
were analyzed by Fourier Transform Infrared Spectroscopy (FTIR) (Thermo Nicolet
Nexus 670 FT-IR, Madison, WI, USA).

The disks were analyzed in the diffuse

reflectance mode in the wave number range of 400–4000 cm−1. The spectra of the
immersed SCPC disks were compared to the spectra of SCPC before immersion in SBF.
A spectrum for KBr was used as a background.

2.1.5.5 Surface Modification

To analyze the morphology of the SCPC disks after immersion in SBF, images were
obtained by SEM as previously described.
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2.2 In-Vivo Study

2.2.1 Experimental Setup

2.2.1.1 General Experimental Protocol

Nine male New Zealand White Rabbits (3 kg, Myrtle's Rabbitry, Thompson Station, TN,
USA) were used to evaluate tissue response to the SCPC implant. The rabbit ulna was
subjected to CT scan and the CT file was used with a Z-Corp machine to make a bone
prototype employing SCPC powder. To induce osteoinduction, the SCPC implant was
loaded with 10 µg of rhBMP-2. rhBMP-2 was used because of its significant role in
inducing bone cell differentiation, which is well documented in the literature [1, 2, 7-9,
23, 24]. Surgical procedures were performed to remove a 10 mm segment of the ulna and
then the defect was grafted with the SCPC-rhBMP-2 hybrid. Plates and screws were used
to provide initial fixation. After 12 or 16 weeks the animals were euthanized. The
morphology and mechanical strength of the regenerated bone were analyzed.

2.2.1.2 Prototype Processing

Prior to surgery, the rabbits had CT scans (Siemens Somatom Plus 4, Siemens Somatom
Sensation 10, Erlangen, Germany) performed on their right forearms. For the CT scans
the rabbits were anesthetized with 10 mg/kg xylazine subcutaneously and 50 mg/kg
ketamine intramuscularly. The CT data was then converted into STL format, which
remapped the surface data to a series of triangles. These images were then imported into
the Amira CAD software where adjustments could be made (Figures 2.2.1.2 (a-b)).
Using the CAD software, the ulna was isolated from the radius. Then a 10 mm bone
segment was removed in the image; 20 mm proximal to the styloid process (Figure
2.2.1.2 (c-e)). The final CAD image of the defect was then converted back into a STL

26

a

Figure 2.2.1.2 (a-e): Z-Corp Processing
These images are of the CT scan data that has been converted into a CAD file. Figure
2.2.1.2 (a) shows the rabbit legs as they would normally appear.
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b

Figure 2.2.1.2 (a-e): Z-Corp Processing (continued)
These images are of the CT scan data that has been converted into a CAD file.

Figure

2.2.1.2 (b) shows the same image as Figure 2.2.1.2 (a) but with the outer layers removed
so that only the bones can be seen. All of this is done using Amira CAD software. From
here the ulna can be isolated.
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c

Figure 2.2.1.2 (a-e): Z-Corp Processing (continued)
These images show the isolated ulna in the CAD software. Figure 2.2.1.2 (c) shows the
10 mm segment to be sectioned out of the ulna 20 mm proximal to the styloid process.

29

d

Figure 2.2.1.2 (a-e): Z-Corp Processing (continued)
These images show the isolated ulna in the CAD software. Figure 2.2.1.2 (d) shows the
ulna with the segment removed.
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e

Figure 2.2.1.2 (a-e): Z-Corp Processing (continued)
These images show the isolated ulna in the CAD software. Figure 2.2.1.2 (e) is an
enlarged image of the 10 mm segmental defect to be replicated using the SCPC powder
and fabricated using the Z-Corp processing RP technique.

It can be seen that the

geometry and topography of the defect is complicated.
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format, and then into a slice file that the Z-Corp machine used to replicate the removed
bone segment layer by layer. To synthesize the desired implant, the Z-Corp spread out a
thin layer of the SCPC powder, then the ink-jet printer head printed a water-based binder
in the cross-section of the implant being created. The build piston which had the SCPC
powder then would drop down, making room for the next layer, and the process was
repeated until an implant that exactly replicated the removed bone segment had been
processed.

2.2.1.3 Thermal Treatment

The implants processed by the Z-Corp were heat treated at 450 ºC for 18 hours to burn
off the binder used to secure the layers and any other hydrocarbons and then at 800, 850
or 900 ºC for 3 hours to sinter the SCPC implants.

2.2.1.4 Sterilization

Prior to surgery, the implants were sterilized by immersing them in 70% ethanol for 30
minutes under a sterile hood. Tweezers, used for handling the implants, were also
immersed in ethanol. After sterilization, the implants were placed in sterile cell culture
dishes to dry.

2.2.1.5 Construct of SCPC-rhBMP-2 Scaffold

In order to reconstitute the rhBMP-2, 40 µl of 4mM HCl containing 0.1% BSA was
sterilized by filtering through a 45 µm pore opening and then dispensed into a vial
containing 10 µg of rhBMP-2. The BSA was added to prevent loss in activity caused by
non-specific binding of BMP to the inside surface of the vial. The BMP solution was
immediately dispensed evenly on all sides of the sterilized SCPC implant.
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2.2.1.6 Surgery

Rabbits were anesthetized with an intravenous injection of 10 mg/kg xylazine followed
by 50 mg/kg ketamine. The right forearm was shaved and the skin was sterilized with
povidone-iodine and draped with sterile towels. Under aseptic conditions, the right ulna
was exposed through a straight incision of approximately 3 cm long. The ulna was
separated from the surrounding muscles and the periosteum was cut through to expose
the ulna bone. A critical sized segmental defect was then created in the ulna of the right
forelimb by removing 10 mm of midshaft diaphyseal bone 20 mm proximal to the styloid
process.
The SCPC implant, thermal treated at 800 (n=1), 850 (n=2) or 900 ºC (n=6), was placed
in the defect. The implant, made individually for each rabbit using the Z-Corp machine,
was secured in place using plate and screws. Using Vicryl, the incision was closed
subcutaneously layer by layer, to prevent the rabbit from chewing out any sutures. Then
skin glue was placed over the outside of the incision. The rabbits received 0.05 mg/kg
buprenorphine 30 minutes prior to the end of surgery and then every 8 to 12 hours as
needed for pain. After recovery, the rabbits were allowed to be load bearing without
external support on the leg.
Two rabbits died prior to surgery, during anesthetizing, due to unknown complications.
These rabbits were to have received SCPC implants thermally treated at 850 ºC.

2.2.2 Evaluation of SCPC-rhBMP-2 Graft

2.2.2.1 Radiographic Evaluation

In order to evaluate bone formation, union and remodeling of the defect, CT scans were
performed postoperatively at 4, 8, and 12 weeks. The CT scans were performed at 64
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slices per rotation with an isotrope CT resolution of 0.4 mm. The high resolution CT data
was then converted into STL data format, remapping the surface data into a series of
triangles, and then imported into a CAD file. This allowed for a non-invasive 3-D view
of the remodeled defect.

2.2.2.2 Histology

The ulna treated with an 800 ºC thermally treated SCPC-rhBMP-2 hybrid implant was
harvested from a rabbit that was euthanized by an overdose of sodium pentobarbital 16
weeks post-operatively. This ulna was used for non-decalcified histological evaluation.
The bone specimen was fixed in 10% buffered formalin solution and then embedded in
polyethlymethacrylate (PMMA), and the non-decalcified sections (40 µm) were ground
and prepared using an Exakt machine (Exakt Technologies, Inc., Oklahoma City, OK).
The sections were made along the long axis of the ulna and were stained with Toluidine
Blue and examined for histological evaluation.

2.2.2.3 Torsional Testing

In order to assess the mechanical properties of the rabbit ulna, the ulna was subjected to
torsional testing. Each rabbit treated with a 900 ºC thermally treated SCPC-rhBMP-2
hybrid implant was euthanized at 12 weeks postoperatively. Both ulnae (grafted (n=3)
and ungrafted (n=3)) from each rabbit were harvested, cleaned of soft tissue and used for
mechanical testing. Specimens with insufficient bone healing (n=3), due to failure of the
fixation device, were excluded from torsional testing. The fixation devices on those
ulnae with sufficient healing were carefully removed. Care was taken to ensure that no
excessive mechanical loads were applied to these ulnae during the harvesting process.
Each harvested ulna was then immediately wrapped in gauze moistened with Ringers
solution, sealed in a labeled storage bag, and then fresh frozen at -20 ºC until testing.
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All ulnae to be mechanically tested were defrosted by removing them from the freezer
and storing them in a refrigerator at 2 °C for 24 hours prior to testing, while still wrapped
with gauze moistened with Ringers solution. Then the ulnae were removed from the
sealed storage bag and prepared for testing by trimming the grafted ulna with a slow
speed diamond wafer saw blade subjected to constant irrigation at sites 2 cm proximal
and distal from the proximal and distal defect ends, so that the total length of the testing
sample was 5 cm. The ungrafted ulna was also isolated and trimmed at the corresponding
sites so it too had a length of 5 cm.
Once the ulnae were at the appropriate length, both ends of the bone were inserted into a
custom-made alignment fixture, and 1 cm of each end of the ulna was potted in JB Weld.
This custom made alignment fixture was used to ensure that the longitudinal axis of the
bone was parallel and concentric with the torsional testing axis. It also ensured that the
gauge length (the total length of the ulna unpotted) was consistent to ±1 mm, and this
amount was measured by using a pair of digital outside vernier calipers accurate to 0.01
mm. During the healing of the bone defect, bony fusion had occurred between the ulna
and the radius. Separation of the radius from the ulna was not possible due to the fibrous
fusion. All limbs were kept physiologically moist by keeping the gauze moistened with
Ringers solution continually wrapped around the ulnae throughout the potting and testing
procedures.
After approximately 24 hours of room temperature hardening, the potted specimens were
mounted in a custom built torsional testing fixture which was secured to a computercontrolled, biaxial servo-hydraulic material testing system (Instron 8521, Canton, MA,
USA). Mechanical testing to failure was performed at room temperature. With the
proximal end held fixed, the distal end was externally rotated at a constant rate of 90
°min−1 until failure. For those specimens with no clear failure, the maximum rotation and
energy to failure was computed for a displacement up to 35 º. Torque versus angular
deformation curves were obtained by using the accompanying Instron System 8800
Controller. Maximum torsional load to failure and angle at failure were measured.
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After the specimens had catastrophically failed, the cross-sectional areas of the ulnae
were obtained by sectioning with a diamond wafer saw blade subjected to continuous
irrigation. These cross-sections were photographed, and the cross-sectional areas were
calculated by using image analysis freeware (NIH Image 1.59, Bethesda, MD, USA).
The calculated cross-sectional area data, along with the gauge length and other measured
torsional test data were then used to calculate the values of maximum torsional load to
failure and torsional angle at failure for grafted and control ungrafted bone. All broken
torsional testing specimens were properly labeled with an indelible ink marker and
returned to their marked storage bags, and then refrozen in the event that additional study
was needed.

2.3 Statistical Analysis

Representative values of parameters used in this study were shown as mean ± standard
deviation.

Each parameter was statistically analyzed by a t-test with two samples

assuming unequal variances.

A p-value of less than 0.05 was considered to be

statistically significant.

Copyright © Amanda Peter Hart 2005
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Chapter 3
Results

3.1 Material Characterization

3.1.1 Morphology Analysis

SEM of the SCPC disks processed using the Z-Corp machine and thermally treated at
800, 850, and 900 ºC showed the disks to be highly porous with interconnected pathways
between the pores (Figure 3.1.1 (a-d)). For all thermal treatment temperatures at high
magnification, a porous structure containing micropores of size range 20-100µm is
visible and the interconnections between these pores are in the range of 10 - 50 µm.
Figure 3.1.1 (a) shows two large micropores that are surrounded by interconnected
pathways in a disk treated at 800 ºC. Figure 3.1.1 (b) shows that the disk treated at 850
ºC has a similar structure of micropores and interconnections. Figure 4.1.1 (c) shows that
pores on the SCPC disk thermally treated at 900 ºC has smoother edges and are more
defined. The micrographs show that as the thermal treatment temperature of the SCPC
disks is increased the particle edges become smoother showing a greater level of
interconnectivity between the pores. Moreover, at a higher magnification, it can be seen
that the surface of the SCPC disks are covered by nanopores (Figure 3.1.1 (d)).

3.1.2 Porosity Measurements
Table 3.1.2 summarizes the results from the porosity and surface area analysis. The
analysis of the porosity shows that the porosity is greatest for the SCPC disks thermally
treated at 800 ºC with a porosity percent of 54%, then 50% at 850 ºC, and then 900 ºC
had the porosity percent of 44%. The surface area of the thermally treated SCPC disks
also was greatest for the lower sintering temperature. The disks treated at 800 ºC had a
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a

Figure 3.1.1 (a-d): SEM Micrographs Before Immersion
SEM micrographs of SCPC disks show that the particle edges become smoother as the
thermal treatment temperature is increased. (a) Two large micropores (dashed lines) of
the disks treated at 800 ºC are surrounded by interconnected pathways of smaller pores
(arrows).
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b

Figure 3.1.1 (a-d): SEM Micrographs Before Immersion (continued)
SEM micrographs of SCPC disks show that the particle edges become smoother as the
thermal treatment temperature is increased. (b) Disks treated at 850 ºC show a similar
structure of micropores (dashed lines) and smaller interconnected pores (arrows).
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c

Figure 3.1.1 (a-d): SEM Micrographs Before Immersion (continued)
SEM micrographs of SCPC disks show that the particle edges become smoother as the
thermal treatment temperature is increased. (c) Disks treated at 900 ºC show more
defined micropores (dashed lines) and interconnection (arrows) with smoother edges.
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Figure 3.1.1 (a-d): SEM Micrographs Before Immersion (continued)
SEM micrographs of SCPC disks show that the particle edges become smoother as the
thermal treatment temperature is increased. (d) High magnification of the disks treated at
850 ºC reveal that the disks are not only microporous, but the surface is also covered with
nanopores (arrows), providing for a large surface area for drug delivery.
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Table 3.1.2: Porosity Analysis
Porosity analysis shows that the porosity percent and surface area were dependent on the
thermal treatment of the SCPC disks.

As the thermal treatment temperature was

increased the porosity percent and surface area both decreased.

As determined by BET and

Pore Size Distribution %

Hg intrusion

Treatment
Temperature

356-100

100-25

25-10

10-1

1 µm-

Surface Area

Porosity

2

µm

µm

µm

µm

4 nm

(m /g)

%

800 ºC

3.00

22.86

48.76

22.42

2.96

3.442

54

850 ºC

2.71

7.12

70.71

17.88

1.57

2.814

50

900 ºC

4.74

12.73

60.36

19.69

2.48

2.615
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surface area of 3.442 m2/g, then 2.814 m2/g at 850 ºC, and those treated at 900 ºC had a
surface area of 2.615 m2/g. As for the pore size distribution, the thermal treatment
temperature had no effect on the distribution of pores greater than 100 µm or less than 10
µm. However, for the SCPC disks treated at 800 ºC, 48.76% of the pores were in the
range of 25 µm-10 µm while 22.86% were in the range of 100 µm-25 µm. When the
thermal treatment was changed to 850 ºC, the percent of pores in the range of 25 µm-10
µm jumped up to 70.71% and the percent dropped to 7.12% in the 100 µm-25 µm range.
For the disks treated at 900 ºC, the percent of pores in the range of 25 µm-10 µm
decreased down to 60.36% and the percent of pores in the range of 100 µm-25 µm
increased to 12.73%.

3.1.3 Mechanical Testing
The mechanical properties of the SCPC disks were dependent on the thermal treatment
temperature (Table 3.1.3).

The compressive strengths and modulus of the disks

significantly increase with the increase of the thermal treatment temperature (n=5,
p<0.04). The ultimate compressive strength and the compressive modulus of the disks
range from 5-15 MPa and 300 MPa-1.1 GPa, respectively. The disks treated at 900 ºC
have a significantly higher compressive strength and modulus as compared to those disks
treated at 800 ºC (p<0.003) and 850 ºC (p<0.003). Moreover, the disks treated at 850 ºC
have a significantly higher compressive strength and compressive modulus as compared
to the disks treated at 800 ºC, p<0.008 and p<0.0006, respectively. These results are
consistent with the SEM results showing that as the thermal treatment temperature
increased, there is greater interconnectivity between the SCPC particles, and thus greater
mechanical strength. Conversely, as the porosity percent of the SCPC disks is increased
the mechanical strengths decrease.
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Table 3.1.3: Mechanical Properties Results
Mechanical properties of the SCPC disks after thermal treatment indicate that the
ultimate compressive strength and the compressive modulus of the disks increased as the
thermal treatment temperature increased. The ultimate compressive strength of the disks
(5-15 MPa) is comparable to that of trabecular bone (2-12 MPa). However, as the
porosity percent increased (Table 3.1.2) the mechanical strength decreased.

Treatment
Temperature

Ultimate
Compressive

Failure Strain

Strength

Compressive
Modulus

800 ºC

5.584 ± 0.52 MPa

0.0198 ± 0.003

307 ± 44MPa

850 ºC

8.977 ± 1.60 MPa

0.0164 ± 0.002

551± 56 MPa

900 ºC

15.326 ± 2.95 MPa

0.0138 ± 0.005

1095 ± 164 MPa
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3.1.4 Release Kinetics of rhBMP-2
Analysis of the release kinetics of rhBMP-2 from the SCPC-rhBMP-2 hybrid and the
HA-rhBMP-2 hybrid showed that after 2 days the concentration of rhBMP-2 released was
not significantly different between the two (Figure 3.1.4). However, after 2 days, the
amount of rhBMP-2 released from the SCPC-rhBMP-2 hybrid is significantly greater
(p<0.04), than that of the HA-rhBMP-2 hybrid. At 14 days the concentrations of rhBMP2 is not significantly different between the two hybrids.

3.2 Interaction of SCPC with SBF
3.2.1 ICP
ICP analyses of the ionic concentrations of SBF for calcium (Ca), phosphorus (P), silicon
(Si) and sodium (Na) after immersing thermally treated SCPC disks in the SBF are shown
in Figure 3.2.1 (a-d). Analysis shows that the Ca concentration of the SBF incubated
with all SCPC disks drops drastically after the first 12 hours of immersion (Figure 3.2.1
(a)). Moreover, thermal treatment has a profound effect on the corrosion behavior of the
material.

The Ca concentration of SBF incubated with SCPC treated at 800 ºC is

significantly (n=3, p<0.03) higher than the Ca concentration of SBF incubated with
SCPC treated at 850 and 900 ºC. However, the difference in Ca concentration of the SBF
incubated with SCPC treated at 850 or 900 ºC is not significantly different. After 12
hours, the Ca concentration of the SBF decreases according to the temperature of the
treatment of the ceramic in the order 800 ºC > 850 ºC > 900 ºC. Similar concentrations
of Ca are measured in the immersion solution after 12 hours, and 1, 3, and 5 days for all
disks which indicates equilibrium between the dissolution and precipitation reactions at
the material-solution interface.
In contrary to the immediate decrease in the Ca concentration, the P concentration
significantly increases after the first 12 hours and then after 1 day begins to slope down
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Figure 3.1.4: Cumulative Release of rhBMP-2 from SCPC and HA
The graph of the cumulative release of rhBMP-2 from the SCPC implant and the HA disk
shows that the release from the SCPC implant is greater than that from the HA disk. This
release was significantly more (p<0.04) from 4-12 days.
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Figure 3.2.1 (a-d): ICP Results
ICP results show the ionic concentrations of SBF incubated at 37 ºC with thermally
treated SCPC disks. (a) The Ca concentration of SBF decreased due to the precipitation
of a HA layer onto the SCPC surface.
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Figure 3.2.1 (a-d): ICP Results (continued)
ICP results show the ionic concentrations of SBF incubated at 37 ºC with thermally
treated SCPC disks. (b) In contrary to the Ca decrease, the P concentration of SBF
increased due to not all P ions dissolving from the material being consumed in the
formation of a HA surface layer.
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Figure 3.2.1 (a-d): ICP Results (continued)
ICP results show the ionic concentrations of SBF incubated at 37 ºC with thermally
treated SCPC disks. (c) The Si concentration increased as the immersion time increased.
This was due to its dissolution from the SCPC disk into the SBF, allowing for the
nucleation of a HA layer apart form the SCPC disk.
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Figure 3.2.1 (a-d): ICP Results (continued)
ICP results show the ionic concentrations of SBF incubated at 37 ºC with thermally
treated SCPC disks. (d) The Na concentration of the SBF increased as the immersion
time increased. As the SCPC disk was immersed, there was dissolution of Na from the
SCPC into the SBF.
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and plateau out (Figure 3.2.1 (b)). The ICP results also show that the thermal treatment
temperature has a significant effect on the corrosion of P. After 12 hours of immersion,
the P concentration of the SBF decreases according to the thermal treatment temperature
of the ceramic in the order 850 ºC > 800 ºC > 900 ºC. The SBF incubated with SCPC
disks thermally treated at 850 ºC has a significantly higher (n=3, p<0.02) P concentration
than the P concentration of SBF incubated with SCPC treated at 850 ºC, which is in turn
significantly higher (n=3, p<0.01) than the P concentration of SBF incubated with SCPC
treated at 900 ºC. Even with these significant differences, they all follow the same trend
of significantly increasing after the first 12 hours and then after 1 day through the rest of
the immersion time begin to plateau out. This plateau shows that the P concentrations of
the SBF are reaching the equilibrium state in the same way that the Ca concentrations are,
and for the same reason.
The Si concentration of the SBF exhibits a significant linear increase for the duration of
the immersion times (Figure 3.2.1 (c)). After all immersion times, the Si concentration of
the SBF incubated with SCPC disks shows that the thermal treatment has a major impact
on the corrosion behavior of the SCPC disks. The Si corrosion increased according to the
thermal treatment temperature of the ceramic before immersion in the order 850 ºC > 800
ºC > 900 ºC. The SBF incubated with SCPC disks thermally treated at 850 ºC has a
significantly higher (n=3, p<0.03) Si concentration than the Si concentration of SBF
incubated with SCPC treated at 800 ºC, which in turn is also significantly higher (n=3,
p<0.03) than the Si concentration of SBF incubated with SCPC treated at 900 ºC.
Nevertheless, even with these significant differences, they all follow the trend of
increasing linearly through 3 days of immersion. After 3 days, the Si concentration of the
SBF incubated with SCPC thermally treated at 800 and 850 ºC begins to show signs of
leveling off. Conversely, the Si concentration of the SBF incubated with SCPC treated at
900 ºC continues to increase.
The concentration of Na of the SBF also increases gradually as the immersion duration
progresses (Figure 3.2.1 (d)).

For the Na concentrations, the thermal treatment

temperature of the SCPC disks has little effect on their corrosion, showing no significant
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differences in the concentrations. The Na concentration of the SBF incubated with the
thermally treated SCPC disks increases from the initial concentration to 12 hours of
immersion and then begins to plateau out after 12 hours of immersion. The concentration
of the SBF incubated with the disks treated at 800 and 900 ºC continues to level off after
3 days of immersion and then begins to increase again. The Na concentration of the SBF
incubated with the disks treated at 850 ºC also begins to level off after 12 hours of
immersion, but unlike the other thermal treatment temperatures, begins to increase again
after 1 day of immersion. Even so, these differences are no statically significant, so the
thermal treatment of the SCPC disks does not affect the Na concentration of the SBF that
they are immersed in.

3.2.2 FTIR
Prior to immersing the SCPC disks in SBF, FTIR spectra of the SCPC surface at all
thermal treatment temperatures demonstrate similar function groups, including distinct Si
signals (Figure 3.2.2 (a-c)). These signals include the Si─O bending mode at 520 cm-1
and S─O vibrational stretch at 1098 cm-1. The peak at 848 cm-1 is a result of the P─OH
stretching mode of HPO4. Peaks that are characteristic for the bending vibrational modes
of P─O are demonstrated at 568, 611, and 1052 cm-1. The shoulder peak at 925 cm-1 is
due to Si ─O-+Na bonds that occur in the SCPC composite.
After 12 hours of immersion in SBF, FTIR spectra for the different thermal treatment
temperatures of SCPC disks demonstrate altered surface functional groups.

The

immersion in SBF causes the development of a new peak for C─O vibrational mode of
carbonate at 860 cm-1. Peaks for P─O, characteristic of carbonate hydroxyapatite, are
observed at 565, 605, and 1035 cm-1. As the presence of new peaks demonstrates the
formation of a hydroxyapatite layer on the surface of the SCPC disks, the peaks
characteristic for Si─O-+Na and Si─O vibrational stretch become less prominent.
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Figure 3.2.2 (a-c): FTIR Results
FTIR results show that after 12 hours of immersion in SBF, the surface of the SCPC
disks was altered similarly for all three thermal treatment temperatures. Characteristics
of a HA later are noted by the P─O peaks at 568 and 1052 cm-1, and the shoulder at 605
cm-1. In addition, the Si─O peaks decreased on the surface of the SCPC disks which
correlates with the ICP results (Figure 3.2.1 (c)). (a) Disks thermally treated at 800 ºC.
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Figure 3.2.2 (a-c): FTIR Results (continued)
FTIR results show that after 12 hours of immersion in SBF, the surface of the SCPC
disks was altered similarly for all three thermal treatment temperatures. (b) Disks
thermally treated at 850 ºC. (c) Disks thermally treated at 900 ºC.
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3.2.3 Surface Modification
The SEM micrographs in Figure 3.2.3 (a-c) confirms the formation of a HA layer on all
SCPC disks after 12 hours of immersion in SBF. The SEM micrograph (Figure 3.2.3 (a))
of the SCPC disk treated at 800 ºC shows a HA layer that is in its early stages of
development. The apatite crystals are dense but they are small. This correlates with the
FTIR spectra that show P─O peaks that are characteristic of HA formation but that are
not strong peaks. The micrograph (Figure 3.2.3 (b)) shows that the apatite formation on
the surface of the SCPC disk thermally treated at 850 ºC is denser and more developed
than the other thermal treatment temperatures. The surface of the SCPC disk is not
visible through the apatite formation. The FTIR spectra shows the P─O shoulder at 605
cm-1 to be more defined for the SCPC disk thermally treated at 850 ºC, which
distinguishes the apatite layer seen in Figure 3.2.3 (b). For the 900 ºC disk, the HA
crystals are large (Figure 3.2.3 (c)), but the surface of the SCPC disk can be seen. Again,
the FTIR spectra confirmed the formation of the HA layer on the surface of the SCPC
disk thermally treated at 900 ºC.
After 1 day of immersion in SBF, the SEM micrographs (Figure 3.2.3 (d-f)) show HA
layers that are more developed and that fully cover the surfaces of the thermally treated
SCPC disks. The formation of the HA layer is confirmed by FTIR results (Figure 3.2.2
(a-c)) and correlates well with the significant decrease in the Ca concentration of the SBF
during immersion.

3.3 SCPC-rhBMP-2 Hybrid Implantation

3.3.1 Radiographs
Data from a CT scan that was performed 4 weeks postoperatively on the rabbit ulna that
was implanted with an 850 ºC thermally treated SCPC-rhBMP-2 hybrid, was converted
into STL format allowing for a 3-D view of the bone. Figure 3.3.1 (a-b) shows that over
65% of the critical sized defect, initially 10 mm long, has been replaced by newly formed
bone. The CT scan images show the significant bone healing and regeneration, as well as
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a

Figure 3.2.3 (a-f): SEM Micrographs After Immersion
SEM micrographs of the SCPC disk surface show that for all thermal treatment
temperatures a HA layer had formed after only 12 hours of immersion in SBF. After 24
hours of immersion, these layers became denser. (a) Disks treated at 800 ºC show a
dense layer of small apatite crystals (2 µm) after 12 hours of immersion.
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b

Figure 3.2.3 (a-f): SEM Micrographs After Immersion (continued)
SEM micrographs of the SCPC disk surface show that for all thermal treatment
temperatures a HA layer had formed after only 12 hours of immersion in SBF. After 24
hours of immersion, these layers became denser. (b) Disks treated at 850 ºC show larger
apatite crystals (5 µm) that cover the surface.
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Figure 3.2.3 (a-f): SEM Micrographs After Immersion (continued)
SEM micrographs of the SCPC disk surface show that for all thermal treatment
temperatures a HA layer had formed after only 12 hours of immersion in SBF. After 24
hours of immersion, these layers became denser. (c) Large apatite crystals (5 µm) are
less dense on the disks treated at 900 ºC.
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Figure 3.2.3 (a-f): SEM Micrographs After Immersion (continued)
SEM micrographs of the SCPC disk surface show that for all thermal treatment
temperatures a HA layer had formed after only 12 hours of immersion in SBF. After 24
hours of immersion, these layers became denser. (d) After 24 hours of immersion, the
800 ºC disks a more dense formation of the smaller apatite crystals.
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Figure 3.2.3 (a-f): SEM Micrographs After Immersion (continued)
SEM micrographs of the SCPC disk surface show that for all thermal treatment
temperatures a HA layer had formed after only 12 hours of immersion in SBF. After 24
hours of immersion, these layers became denser. (e) The disks treated at 850 ºC have a
thick apatite layer consisting of large apatite crystals.
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Figure 3.2.3 (a-f): SEM Micrographs After Immersion (continued)
SEM micrographs of the SCPC disk surface show that for all thermal treatment
temperatures a HA layer had formed after only 12 hours of immersion in SBF. After 24
hours of immersion, these layers became denser. (f) The large apatite crystals cover more
of the surface, but the SCPC material can still be seen through the hydroxyapatite layer.
These results are consistent with the ICP and FTIR results (Figure 3.2.1 (a-d) and 3.2.2
(a-c)).
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b

Figure 3.3.1 (a-d): Radiographic Evaluation
Initially a 10 mm long segmental defect was created in the ulna. (a) The dashed lines
refer to the original edges of the defect, and the arrows point to the plate that was used to
provide the initial support in the leg. Approximately 65% of the implant has been
replaced by regenerated bone. (b) This shows the healing on the other side of the ulna
defect. The black circles represent the place of the screws inserted into the plate to
provide initial fixation and stability.
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Figure 3.3.1 (a-d): Radiographic Evaluation (continued)
Digital images were taken of the rabbit ulna grafted with the SCPC-rhBMP-2 hybrid
implant 16 weeks post-operative. (c) This image shows the superior side of the ulna and
radius which have become fused during the healing of the 10 mm defect (dashed lines
refer to the original edges defect). The implant can barely be distinguished from the bone
due to the abundant formation of new bone.

In this regenerated bone the high

vascularization can be seen.
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Figure 3.3.1 (c-d): Radiographic Evaluation (continued)
Digital images were taken of the rabbit ulna grafted with the SCPC-rhBMP-2 hybrid
implant 16 weeks post-operative. (d) Exceptional healing on the inferior side of the ulna
can also be seen. After 16 weeks the resorbable implant shows near complete healing of
the defect. These images confirm the in-vitro results that showed the SCPC implant to be
both bioactive and resorbable.
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full implant integration, all which can be observed non-invasively during the healing
process.
After 16 weeks post-operative, the rabbit was euthanized and the ulna was harvested and
the surrounding tissue was removed. Digital images of the superior and inferior sides of
the ulna show almost complete healing of the 10 mm critical sized segmental defect
(Figure 3.3.1 (c-d)). Figure 3.3.1 (c) also shows the large amount of vascularization
taking place in side the new bone formation.

3.3.2 Histology
After 16 weeks of implantation, the segmental defect in the rabbit ulna implanted with
the 800 ºC thermally treated SCPC-rhBMP-2 hybrid was filled with mature bone and
osteocytes. Histological analysis of the grafted ulna shows abundant bone formation, and
bony bridging of the defect can be observed (Figure 3.3.2 (a-b)). Some remnants of the
SCPC biomaterial are present, with bone formation directly on their surface. In general,
these remnants are incorporated in newly formed bone, and no inflammatory reactions
could be detected. The mature bone is also highly vascularized evident by the numerous
blood vessels filled with red blood cells. In addition, osteoblasts can be seen actively
forming new bone.

3.3.3 Torsional Testing
Table 3.3.3 is a summary of the torsional testing results comparing the ulna implanted
with a 900 ºC thermally treated SCPC-rhBMP-2 graft to the ungrafted rabbit ulna. The
mechanical testing of the ulna grafted with the SCPC-rhBMP-2 hybrid (n=3) as
compared to the control ulna with no graft (n=3) shows that the maximum torsional load
to failure is significantly higher (p<0.04) for the ulna grafted with the SCPC-rhBMP-2
hybrid. In comparing the angle at failure there is not a significant difference between the
grafted and ungrafted ulna. These results are normalized for the cross-sectional area
which is greater for the grafted ulna which has fused with the radius.
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a

Figure 3.3.2 (a-b): Histological Analysis
Histological analysis of the rabbit ulna after 16 weeks of implantation showed that the
SCPC-rhBMP-2 implant had been replaced by regenerated mature bone. (a) This image
shows that the regenerated bone is highly vascularized. Black arrows point to the blood
vessels containing red blood cells indicating vascularization of the regenerated bone
tissue. In addition, osteocytes (red arrows) can be seen in the mature mineralized tissue.
Remnants of the SCPC material (white arrows) are incorporated in the newly formed
bone and osteoblasts (yellow arrows) can be seen actively forming new bone.
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Figure 3.3.2 (a-b): Histological Analysis (continued)
Histological analysis of the rabbit ulna after 12 weeks of implantation showed that the
SCPC-rhBMP-2 implant had been replaced by regenerated mature bone. (b) A closer
look shows the large number of red blood cells (white arrows) in the regenerated bone.
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Table 3.3.3: Torsional Testing Results
Torsional testing of the ulna grafted with the SCPC-rhBMP-2 hybrid and the ungrafted
ulna showed that the maximum torsional load to failure was significantly greater (p<0.04)
for that of the grafted ulna. However, there was not a significant difference between the
angles at failure for the grafted ulna as compared to the ungrafted ulna.
Maximum Torque (Nm)

Angle at failure (rad)

Ungrafted

Grafted

Ungrafted

Grafted

1

13.4

16.457

0.43

0.195

2

5.359

25.099

0.285

0.608

3

3.92

18.652

0.249

0.541

Rabbit No.

Mean ± SD 7.56 ± 5.11 20.07 ± 4.49 0.32 ± 0.10 0.45 ± 0.22
p

0.04*

0.43

*indicates significant difference

Copyright © Amanda Peter Hart 2005
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Chapter 4
Discussion

4.1 In-Vitro
Through in-vitro testing, the porous, resorbable, bioactive SCPC material was found to
possess both the physical and biological characteristics required to make it a suitable
carrier system for the delivery of rhBMP-2 in a segmental bone defect. The SCPC
material demonstrated high porosity and large pores that were interconnected.
Compression testing showed that although the material was porous, the mechanical
strength was similar to that of trabecular bone. Upon immersion in a physiological
solution, the composite slowly degraded while at the same time a HA layer precipitated
onto its surface. After loading the SCPC with rhBMP-2, the hybrid demonstrated a
sustained release profile for 14 days in a physiological solution.

4.1.1 Material Characterization
SEM micrographs of the bioactive SCPC samples, processed by the Z-Corp 3-D printer
and then thermally treated, showed the samples to be highly porous, providing a large
surface area for enhanced tissue ingrowth (Figure 3.1.1 (a-d)). The interconnectivity of
the pores creates a scaffold that allows for cell and nutrient migration throughout the
entire SCPC sample. If the pores are not interconnected, the cells can only survive at the
surface of the sample, thus vascular and bone ingrowth will never occur.
Since the viability of the regenerated bone depends upon the rate of vascularization it is
critical that the scaffold be porous. In fabricating a biomaterial to replace bone, the intent
is for the internal structure of the scaffold to mimic that of bone. The porosity of cortical
bone ranges from 5% to 30% while cancellous bone porosity ranges from 30% to 90%
[40]. The high porosity of SCPC, 44-54%, facilitated the ingrowth of fibrovascular tissue
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that then ossified and the large pore size range (4 nm-356 µm) of the SCPC scaffold
allowed for cell invasion, vascularization, and nutrients to reach the invaded cells so that
bony ingrowth and osseous integration could occur (Figure 3.3.2 (a-b)). Although
initially it was weaker from a structural standpoint, the porous SCPC material has an
advantage over a solid material in that the pores facilitate the ingrowth of fibrovascular
tissue that then ossified. On the other hand, a nonporous implant would not allow for the
invasion of blood vessels and cells due to its compact structure.
A previous study showed that mineralized bone growth into porous implants requires a
minimum interconnective pore size of 100 µm, the ingrowth of osteoid tissue requires a
minimum pore size between 40 and 100 µm, and the ingrowth of fibrous tissue requires a
minimum pore size between 5 and 14 µm [41]. However, another study reported that not
only a pore size of greater than 50 µm is necessary, but the interconnections play an
important role in bone formation as well [42]. That study reported that to allow for cell
penetration the interconnections size must be greater than 20 µm. Yet, if a material is
resorbable, its pore and interconnection sizes will be modified by degradation upon
contact with a physiological solution. For the SCPC scaffold, although the initial pore
size range was 4 nm-356 µm, and the interconnections range was from 10 µm-50 µm, the
immediate resorption that took place in a physiological solution increased this pore size
range and interconnection size, and synergistically increased the pathways for cell
invasion and vascularization to take place.
Different thermal treatment temperatures of the SCPC composite showed that for
different temperatures, the overall pore and interconnection sizes remained very similar.
However, the distribution of these pore sizes was affected by the thermal treatment. The
pore size ranges that were shown to be affected by the thermal treatment were 10 µm-25
µm and 25 µm-100 µm (Table 3.1.2). In addition, as the sintering temperature was
increased, the porosity percent was decreased. This was due to a greater amount of
fusion between the particle edges, and although the pore sizes were not changed, the
porosity percent was decreased with increasing temperature. The decrease in the porosity
percent of the SCPC is directly related to the surface area, which also decreased with
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increasing thermal treatment temperature. Nevertheless, due to SCPC being a resorbable
biomaterial, the differences in porosity and pore size distribution due to different thermal
treatment temperatures are negligible. Upon immersion in a physiological solution, the
material begins to be resorbed and the pore sizes and porosity immediately changed.

4.1.1.1 Hydroxyapatite Layer
Moreover, the high porosity of SCPC provided a high surface area in contact with tissue
fluids and cells, which in turn enhanced the dissolution/precipitation reactions at the
material surface, leading to the formation of a HA layer (Figure 3.2.3 (a-c)).

The

dissolution of the SCPC in-vivo occurred in two ways, solution-mediated resorption and
cell-mediated

resorption.

The

solution-mediated

resorption

involved

the

dissolution/precipitation reaction that occurred as the exchange of ions took place
between the SCPC and the physiological solution. The cell-mediated resorption involved
the stimulation of osteoclastic resorption of SCPC as seen in Figure 3.3.2 (a). To meet the
requirements of skeletal growth and mechanical function, bone constantly undergoes
dynamic remodeling by a coupled process of bone resorption by osteoclasts and
reformation by osteoblasts. This cell-mediated resorption also occurred upon
implantation of the SCPC implant in rabbit ulna defect; osteoclasts broke down the SCPC
while the osteoblasts formed new bone in its place (Figure 3.3.2 (a)).
Immersion of SCPC in a physiological solution led to formation of an HA layer, which
precipitated onto its surface, as shown by FTIR (Figure 3.2.2 (a-c). The formation of this
HA layer is essential to new bone formation because hydroxyapatite’s chemical and
crystallographic structure is very similar to that of bone mineral. When immersing a
biomaterial, such as SCPC, in a physiological solution the surface chemical reactions
result in the formation of this HA layer to which bone can bond more readily. Therefore,
the essential requirement for a biomaterial to bond to living bone is the formation of a
bone-like apatite layer on its surface in-vivo. One previous study has proven that the SBF,
having almost the same ionic concentration as human blood plasma, can reproduce the
surface changes in-vivo [39]. In addition, the precipitation of a HA layer after immersion
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in SBF has been widely used to assess the degree of bioactivity of a biomaterial [22].
Thus, investigating the biological behavior of bioceramics in SBF is considered to be the
most efficient method to authenticate their bioactivity in the body environment.

4.1.1.2 Mechanical Strength
In replacing bone in a segmental defect, it is important for a porous implant to have initial
mechanical strengths that will allow it to withstand loading until bone regeneration can
occur. A biomaterial must demonstrate equivalent mechanical properties to the type of
bone being replaced, whether it is trabecular or compact bone. However, by virtue of the
need of porosity and resorbability there would be a trade off between the mechanical
strengths and the porosity. This is due to the compressive strength being inversely
proportional to the volume percentage of porosity. Mechanical testing of the thermally
treated SCPC material confirmed that although the samples were porous, their
compressive strengths (5-15 MPa) were similar to that of trabecular bone (2-12 MPa)
(Table 3.1.3). The high compressive strength of SCPC was due to the high thermal
treatment temperature of the SCPC samples which caused the particle edges to fuse with
each other during the sintering reaction.

As the thermal treatment was increased the

mechanical strengths of the material also increased, due to greater fusion of the SCPC
particle edges. However, this increase in strength corresponded to a decrease in porosity
as previously mentioned. Nevertheless, the compressive strengths of the SCPC samples
were similar to trabecular bone, but less than that of compact bone which has a
compressive strength of (100-220 MPa).

Therefore if it used for cortical bone

replacement, as in this study, an external fixation device should be used to provide the
initial support. Then as the porous SCPC implant undergoes biodegradation, it is slowly
replaced by bone. The strength of the implant in the defect will gradually increase as the
new bone grows into the porous network of the SCPC implant. Although a nonporous or
compact scaffold would have higher mechanical properties, as previously stated, a solid
material would not allow for the invasion of cells and blood vessels that are necessary for
new bone to form. In addition, it used as a carrier for growth factors, a solid scaffold
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would cause immediate release of the growth factor, instead of a desired controlled
release.

4.1.1.3 Geometry
For a bone tissue engineering scaffold to successfully regenerate bone in a defect and be
capable of supporting cell proliferation, its internal as well as external geometry must
replicate natural bone [40]. By fabricating the SCPC using the Z-Corp processing, a SFF
technology, a scaffold that mimics the internal and external architecture of natural bone
was created. Upon implantation in-vivo this scaffold acted as a placeholder for the
induction of new bone. As can be seen in Figure 3.3.1 (c-d), bone mass developed in the
size and shape of the Z-Corp processed SCPC scaffold.

The external shape and

topography of natural bone is very complex; no bone in the body is perfectly square or
cylindrical. This is why it is necessary to fabricate bone tissue engineering scaffolds that
exactly replicate bone. Z-Corp processing of the SCPC material allowed for this.

4.1.2 rhBMP-2 Release Kinetics
When a bone tissue engineering scaffold is used as a carrier for BMP, it must have a
controlled release of the BMP, so that the protein is retained at the grafted site for a
period of time sufficient to stimulate cell differentiation and induce bone formation. It is
desirable to have a bulk release of BMP initially, followed by a more gradual release
thereafter [20]. Many studies have investigated the ability of calcium phosphate ceramics
to serve as a delivery system for BMP [9, 43, 44]. However, these studies showed that the
porous ceramic implants demonstrated a very limited release of rhBMP-2. This means
that almost all of the rhBMP-2 was maintained at the cement surface, inhibiting the
protein from exerting its biological action. In our study, upon immersion in a
physiological solution, the SCPC-rhBMP-2 hybrid implant demonstrated a continuous
release of rhBMP-2 for 14 days (Figure 3.1.4). As compared to HA, the SCPC implant
had a greater release of rhBMP-2 over the 14 day period. Due to the high porosity and
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the nanopores of the SCPC implant, the protein had a large surface area with which to
adsorb. The nanopores (Figure 3.1.1 (d)) allowed for a greater surface area for protein
adsorption, they provided protective pockets for the adsorbed protein, and enhanced the
sustained release of rhBMP-2 [45]. This sustained release of rhBMP-2 by SCPC was
demonstrated in-vivo, where the SCPC implant maintained the growth factor at the
defect, stimulating osteoblast differentiation and new bone formation (Figure 3.3.2 (a)).

4.1.3 Interaction of SCPC with SBF

4.1.3.1 Effect of Immersion Duration
ICP analyses indicated that after immersing the resorbable SCPC samples in SBF the Ca
concentration of the SBF decreased linearly until 12 hours while the P, Si and Na
concentrations of the SBF increased (Figure 3.2.1 (a-d)). Figure 3.2.1 (a) shows the
initial decrease in the Ca concentration which was due to the precipitation of a HA layer
onto the surface of the SCPC as has been confirmed by FTIR (Figure 3.2.2 (a-c)) and
SEM (Figure 3.2.3 (a-f)).

FTIR analyses showed that after 12 hours SCPC had

developed a layer consisting of small HA crystallites that completely covered its surface.
SEM analyses showed the homogenous distribution of these HA crystals, having a size of
1 µm, on the surface and in the pores and interconnections. Another study found similar
results when the biomaterial hydroxyapatite was immersed in SBF [46]. They found that
after 1 day the hydroxyapatite surface was completely covered by a layer of precipitates
that nucleated on the surface and in the pores and chasm.
For SCPC, the precipitation of the HA layer occurred concurrently with the initial
dissolution of the ions from the samples. The previously mentioned study with the
hydroxyapatite biomaterial also found that the dissolution of Ca and P and the
precipitation of calcium phosphate occur concurrently, leading to the HA layer on its
surface. Another study investigated the dissolution behavior of HA/BG in SBF [47]. This
study found that at the early stage of immersion, the dissolution preceded faster than the
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eventual precipitation of an apatite layer. In the case of SCPC, as the immersion time
increased beyond 12 hours the Ca concentration of the SBF began to plateau. This was
due to an equilibrium being reached between the precipitation/dissolution interaction of
the SCPC sample and the SBF. This equilibrium exchange of ions indicates the constant
degradation of the resorbable SCPC implant being replaced by a bone-like apatite layer
that formed after just 12 hours of immersion in SBF. In contrast, the study with the
hydroxyapatite biomaterial did not show an equilibrium exchange of ions until after 14
days of immersion.
In contrary to the initial decrease in the Ca concentration of the SBF, the P concentration
initially increased (Figure 3.2.1 (b)). The increase in P concentration of the SBF may be
due to the fact that not all P ions dissolved from the SCPC sample were consumed in the
formation of the HA surface layer. SCPC initially has a Ca to P ratio of 1, however when
Ca and P precipitated after dissolution they precipitated as hydroxyapatite which has a Ca
to P ratio of 1.67. Therefore, the exchange of the Ca and P ions between the SCPC
sample and the SBF resulted in excess P ions in the SBF that were not involved in the
mechanism of the formation of apatite on the SCPC surface. The P concentration began
to level off after 12 hours of immersion. For the remaining immersion time, the P
concentration slightly decreased and, like the Ca concentration, began to plateau. This
again indicates that equilibrium in the precipitation/dissolution interaction had been
reached. The study involving the hydroxyapatite biomaterial showed an initial increase
in P concentration of SBF, and then a decrease. Like the Ca ions, an equilibrium
exchange of P ions for the hydroxyapatite biomaterial was not reached until 14 days of
immersion.
As the immersion time increased the amount of CaP precipitated onto the SCPC sample
also increased, creating a dense HA layer on the surface. Moreover, the FTIR spectra
after 12 hours also showed signals characteristic of a carbonate hydroxyapatite layer that
was noted by the peaks for P─O at 560, 605, and 1030 cm-1 (Figure 3.2.2 (a-c)). Other
studies have attributed these same peaks as the P─O bonds of HA [45, 48-51]. This, in
conjunction with the ICP results, demonstrates that the dissolution of the SCPC in
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physiological solution was followed by the formation of a hydroxyapatite layer known to
stimulate bone cell function.

Similar studies of the effect on the interaction of

hydroxyapatite and bioactive acrylic-glass samples with SBF showed that after 24 hours
and 4 days, respectively, there was a HA layer formed on the surface [46, 52]. The
formation of the HA layer on the SCPC samples after only 12 hours shows the higher
bioactivity of the material. In conjunction, SEM micrographs confirm that after 12 hours
of immersion in SBF, there is formation of a HA layer on the SCPC samples.
Micrographs after 1 day of immersion show a denser HA layer formed that fully covered
the surface of the SCPC samples.
It is also important to note that when the dissolution of the ions from the SCPC sample
takes place, they do not only dissolve from the outer surface of the SCPC but also
throughout the sample. Due to the sample being porous, the SCPC sample can degrade
evenly throughout and the ions from the SBF precipitate throughout the entire SCPC
sample, inside and out. This means that the formation of an HA layer not only occurs on
the outside surface of the SCPC sample, but also throughout the network of pores that
make up the SCPC sample.
The ICP analyses indicated that the Si concentration of the SBF was initially very low but
showed a linear increase for the duration of the SCPC sample being immersed in the SBF
(Figure 3.2.1 (c)). This increase in Si concentration of the SBF reflects the dissolution of
Si ions from the SCPC sample into the SBF. Analysis of the SCPC surface chemistry by
FTIR showed that before immersion in the SBF, the SCPC samples had strong Si─O
peaks due to the silica-rich composition. After 12 hours of immersion in the SBF, these
peaks were no longer distinct. This correlates with the ICP results which showed an
increase in the Si concentration of the SBF after 12 hours. This proves that the Si was
released from the SCPC sample into the immersion solution. Previous studies reported
that the high bioactivity of silicon [53] which when released nucleated HA formation
apart from the SCPC samples. In addition, this dissolution was also beneficial in that as
the silica-rich samples released the silicon, it allowed for the HA layer to form on the
surface in its place. In the current study it was found that the dissolution from the SCPC
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allowed the Si ions to nucleate apatite formation away from the SCPC sample as well as
allowing the Ca and P ions to create an HA layer on and throughout the SCPC in its
place.

Previous studies that have used polymers as a tissue engineering scaffold,

“impregnate” their material with sodium silicate gel, which acts as a nucleating agent to
promote the nucleation and growth of a HA layer on the polymer surface [54, 55]. On the
other hand, one study reported that apatite cannot precipitate on silica-rich surfaces [56].
Consequently, the dissolution of the Si from the SCPC samples not only nucleated apatite
formation away from the implant, but it in its absence allowed for apatite formation on
the surface of the implant.
SEM analysis after immersion in SBF confirms the morphology changes of the SCPC
surface that were demonstrated in the ICP and FTIR results. Micrographs show that
these surface modifications were in the form of HA crystal deposits that cover the surface
of the SCPC scaffold and on the surface.

4.1.3.2 Effect of Thermal Treatment Temperature
The thermal treatment temperature of the SCPC samples had a significant effect on the
interaction between the SCPC and SBF. The significant differences in the corrosion
behavior of the SCPC disks are due to the different thermal treatment they were subjected
to. Each of the thermal treatments causes the SCPC disks to have diverse crystalline
phases. Each of the phases responds differently to being immersed in the SBF and these
differences are shown in the varied ionic concentrations of the SBF at each of the
immersion time periods.

ICP results show that with respect to P, and Si, ion

precipitation/dissolution, the SCPC samples thermally treated at 850 ºC demonstrated a
significantly higher corrosion rate than those samples treated at 800 or 900 ºC (Figure
3.2.2 (a-c)). In conjunction, FTIR spectra showed that after immersion in SBF, the
appearance of peaks for P─O, observed at 560, 605, and 1030 cm-1, which are
characteristics of carbonate hydroxyapatite, were more prominent for those samples
thermally treated at 850 ºC as compared to the other thermal treatment temperatures.
Furthermore, SEM micrographs confirm the formation of a HA layer, showing that SCPC
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samples thermally treated at 850 ºC have a denser apatite layer formed with larger apatite
crystals (Figure 3.2.3 (a-f)). The significant differences in the corrosion behavior of the
SCPC samples were due to the different thermal treatment temperatures they were
subjected to. Each of the thermal treatments caused the SCPC samples to have diverse
crystalline phases. Each of the phases responded differently to being immersed in the
SBF and these differences are shown in the varied ionic concentrations of the SBF at
each of the immersion time periods.
The results of the Material Characterization together with the Interaction of SCPC with
SBF show that the SCPC processed with the Z-Corp 3-D printer is highly porous with a
large surface area and high compression strength and is not only bioactive but is also
resorbable. All of these attributes combined form a scaffold that can serve as a tissue
engineering substitute for autologous bone implant.

4.2 In-Vivo
After obtaining successful results through the in-vitro testing of SCPC, the porous,
resorbable, bioactive biomaterial was tested in-vivo as a carrier for rhBMP-2. The SCPCrhBMP-2 hybrid prepared by a rapid prototyping technique enhanced rapid bone
regeneration in a segmental bone defect in the ulna of rabbit. Implantation of the SCPCrhBMP-2 hybrid into a segmental defect created in the ulna of rabbit showed that after 3
months the resorbable implant had been replaced with new bone and the defect was
almost completely reconstructed. Torsional testing demonstrated that the bone strength
was returned to normal. Histological evaluation showed that the SCPC-rhBMP-2 hybrid
had been replaced by mature bone that has directly formed on the implant surface. These
results indicate that the SCPC-rhBMP-2 can serve as a tissue engineering alternative to
autologous bone grafting.
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4.2.1 Radiographs
CT scans of the rabbit ulna allowed for a non-invasive way to track the progress of the
healing of the segmental defect. After 4 weeks of implantation, significant bone healing
and full implant integration with bone can be observed in the defect grafted with the 850
ºC thermally treated SCPC-rhBMP-2 hybrid (Figure 3.3.1 (a-b)). In addition, direct
apposition of bone onto the implant surface can be seen.

After just 4 weeks of

implantation, the resorbable SCPC-rhBMP-2 hybrid had induced the formation of newly
formed bone that replaced about 65% of the initially 10 mm long critical sized defect.
This rapid healing demonstrates the high bioactivity of the SCPC and the osteoinductive
ability of the rhBMP-2 to differentiate mesenchymal stem cells into osteogenic cells. In
addition, due to the SCPC-rhBMP-2 scaffold being processed using the Z-Corp 3D
printer and made into an exact replica of the defect, this allowed for an intimate contact
between the bone and the implant. Not only did this allow for rapid integration of cells,
but the regenerated bone mass also was formed in the exact size and shape of the natural
bone.
Digital images of the rabbit ulna grafted with the SCPC-rhBMP-2 hybrid harvested after
16 weeks of implantation showed almost complete healing of the defect (Figure 3.3.1 (cd)). Due to the abundant new bone formation, it was barely distinguishable where the
implant had originally been. Figure 3.3.1 (c) showed the high vascularization of the
regenerated bone, indicating the integration of blood vessels throughout the entire
original defect.

4.2.2 Histology
Histological analysis showed newly regenerated bone with a fully developed Haversian
system. As shown in Figure 3.3.2 (a-b) the regenerated bone was highly vascularized and
osteocytes could be seen in the mature mineralized tissue just 12 weeks after implantation
of the SCPC-rhBMP-2 hybrid. Remnants of the SCPC biomaterial were incorporated in
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the newly formed bone, with direct bone apposition on its surface. Differentiated
osteoblasts were observed actively regenerating bone. A study using a combination graft
of rhBMP-2/PLGA in a segmental defect, histologically showed only the abundance of
immature bone after 16 weeks of implantation [57]. Another study using PLGA-coated
gelatin sponge as a carrier for rhBMP-2 in a segmental defect showed similar formation
of bony bridging by newly formed bone after 16 weeks [16]. However, a study that used
porous polyurethane, upon histological evaluation, showed macrophages and giant cells
getting organized around the edges of the porous polymer [8]. The histological evaluation
of the SCPC-rhBMP-2 hybrid showed no signs of an adverse inflammatory reaction. The
histological results indicate that the newly formed bone inside the defects grafted with
SCPC-rhBMP-2 scaffold has all the morphological characteristics of mature bone.

4.2.3 Torsional Testing
To regain complete functionality of bone the new regenerated bone needs to have the
same mechanical strengths as natural bone. As new bone is formed in place of a defect,
the goal is to return the strength of the bone back to normal. Torsional strength of the
rabbit ulna grafted with the 900 ºC thermally treated SCPC-rhBMP-2 hybrid was tested in
comparison to the ungrafted ulna. Restoration of maximum torque and angle at failure of
the regenerated bone to comparable levels of natural bone was seen after 12 weeks of
implantation (Table 3.3.3). Due to the high porosity and bioactivity of SCPC and the
osteoinductive capabilities of rhBMP-2, bone induction occurred rapidly and the
regenerated bone became mechanically equivalent to the original bone. Although direct
comparison between studies is difficult due to differences in experimental techniques, the
results in this study show a similar time frame in the restoration of bone strength. Kokubo
et al. used poly[L-lactide-co-glycolide]copolymer-coated gelatin sponge as a carrier for
BMP in a segmental defect and achieved restoration of maximum torque and angle at
failure to the intact levels after 32 weeks of implantation [13]. However, it was found in
this study that the implant that had initially been processed into a block caused an
increase in diameter of the regenerated bone. This was not found in our study because
the SCPC-rhBMP-2 was fabricated using a Z-Corp 3D printer which allowed for an exact
80

replica of the defect to be made. Another study, using resorbable calcium-phosphate
particles in a segmental defect, found that after 12 weeks, the bone formed in the defect
had relatively poor mechanical strengths due to the resorption of the particles taking
place before complete remodeling of the bone could occur [6]. The high porosity,
bioactivity, and osteoinductive behavior of the SCPC-rhBMP-2 hybrid induced the rapid
formation of bone, which allowed for the regenerated bone to regain complete
functionality after just 12 weeks of implantation.

Copyright © Amanda Peter Hart 2005
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Chapter 5
Conclusion

Bioactive resorbable SCPC, processed using a 3D rapid prototyping technique, created
highly porous scaffolds with interconnected pathways to allow for cell and blood vessel
invasion. In-vitro testing of the SCPC material indicated that the material had high
mechanical properties. In addition, when immersed in physiological solution, the SCPC
material demonstrated controlled dissolution/precipitation reactions that led to the
formation of a biological hydroxyapatite surface layer known to stimulate bone cell
function. When loaded with rhBMP-2, the SCPC-rhBMP-2 hybrid showed a sustained
release of the growth factor. In-vivo testing of the SCPC-rhBMP-2, prepared by a rapid
prototyping technique to create an exact replica of a segment of the rabbit ulna, showed
excellent bone regeneration. This hybrid enhanced bone regeneration in a segmental,
load-bearing bone defect in the ulna of rabbit. Torsional testing of the ulna demonstrated
the restoration of complete functionality after just 12 weeks of implantation. Histological
evaluation showed differentiated osteoblasts and osteocytes in the mature mineralized
tissue. The enhancement of complete bone regeneration after 16 weeks was attributed to
the high bioactivity and resorbability of the material. Both the in-vitro and in-vivo results
indicate that the porous, resorbable, bioactive SCPC-rhBMP-2 hybrid can serve as a
tissue engineering substitute for autologous bone implant.

Copyright © Amanda Peter Hart 2005
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